Inflammation: defence, resolution and persistent activation

Repair requires coordination

Immune cells, tissue cells and chemical signals coordinate defence and repair. A short response can be useful; persistent activation can coexist with altered repair. C-reactive protein is a marker, not a map of every inflammatory pathway. One elevated measurement does not identify the cause or select a supplement. [1] [2]

A clinical test of one pathway

CANTOS randomized 10,061 people with previous myocardial infarction and raised hs-CRP. Canakinumab 150 mg every 3 months reduced recurrent cardiovascular events versus placebo without lowering lipids. Fatal infection was more frequent with canakinumab; all-cause mortality was not significantly reduced. This supports a role for a specific inflammatory pathway in this patient group, not a general claim for anti-inflammatory supplements. [2]

Fibrosis: when repair leaves excess matrix

Fibrosis is excess accumulation of extracellular matrix, including collagen, in tissue. Repeated injury, immune signals and activated matrix-producing cells can reinforce one another. It is not simply “more inflammation”, and reducing a blood marker does not show that established fibrosis has reversed. [1]

CKD is a clinical condition, not a pathway score

Chronic kidney disease (CKD) involves persistent abnormalities of kidney structure or function for more than 3 months with health implications. Kidney function and urine albumin are important to assessment. Inflammation and fibrosis can participate in kidney disease, but CKD cannot be diagnosed from an oxidative-stress marker. Kidney disease also changes the safety context for supplements and requires individualized clinical advice. [3] [1]

Sources & research context

1. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nature Medicine. 2012;18:1028–1040.

   Mechanistic review

   NIH-affiliated authors; used for tissue-repair mechanisms, not current treatment recommendations. Detailed funding/COI verification remains incomplete.

2. Ridker PM et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. NEJM. 2017;377:1119–1131.

   Randomized drug trial · secondary prevention

   Funded by Novartis. Author financial disclosures accompany the paper. The selected patient population, infection risk and lack of significant all-cause mortality benefit matter to interpretation.

3. National Kidney Foundation. What is the Criteria for CKD.

   Professional organization · diagnostic definition

   Organizational guidance, not a supplement trial. Used only for the definition and clinical context of CKD.

First edition. A scientific synthesis of the cited sources, not a systematic review.